Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 9;10(3):412.
doi: 10.3390/antiox10030412.

Antioxidant Therapy in Inflammatory Bowel Diseases

Affiliations
Review

Antioxidant Therapy in Inflammatory Bowel Diseases

Katarzyna Dziąbowska-Grabias et al. Antioxidants (Basel). .

Abstract

Inflammatory bowel diseases (IBD) are a group of chronic, incurable diseases of the digestive tract, the etiology of which remains unclear to this day. IBD result in significant repercussions on the quality of patients' life. There is a continuous increase in the incidence and prevalence of IBD worldwide, and it is becoming a significant public health burden. Pharmaceuticals commonly used in IBD management, for example, mesalamine, sulfasalazine, corticosteroids, and others, expose patients to diverse, potentially detrimental side effects and frequently do not provide sufficient disease control. The chronic inflammation underlies the etiology of IBD and closely associates with oxidative/nitrosative stress and a vast generation of reactive oxygen/nitrogen species. Relative to this, several substances with antioxidant and anti-inflammatory properties are now intensively researched as possible adjunctive or independent treatment options in IBD. Representatives of several different groups, including natural and chemical compounds will be characterized in this dissertation.

Keywords: antioxidant therapy; antioxidants; inflammation; inflammatory bowel diseases; oxidative/nitrosative stress; reactive oxygen/nitrogen species.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The connection between oxidative stress (OS) and inflammatory bowel diseases (IBD) and the key role of the antioxidants. ROS—reactive oxygen species.

References

    1. De Lange K.M., Barrett J.C. Understanding inflammatory bowel disease via immunogenetics. J. Autoimmun. 2015;64:91–100. doi: 10.1016/j.jaut.2015.07.013. - DOI - PubMed
    1. Molodecky N.A., Soon I.S., Rabi D.M., Ghali W.A., Ferris M., Chernoff G., Benchimol E.I., Panaccione R., Ghosh S., Barkema H.W., et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on sys-tematic review. Gastroenterology. 2012;142:46–54. doi: 10.1053/j.gastro.2011.10.001. - DOI - PubMed
    1. Zhang Y.-Z., Li Y.-Y. Inflammatory bowel disease: Pathogenesis. World J. Gastroenterol. 2014;20:91–99. doi: 10.3748/wjg.v20.i1.91. - DOI - PMC - PubMed
    1. Beaugerie L., Brousse N., Bouvier A.M., Colombel J.F., Lemann M., Cosnes J., Hébuterne X., Cortot A., Bouhnik Y., Gendre J.P., et al. CESAME Study Group. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: A prospective observational cohort study. Lancet. 2009;374:1617–1625. doi: 10.1016/S0140-6736(09)61302-7. - DOI - PubMed
    1. Connor V. Anti-TNF therapies: A comprehensive analysis of adverse effects associated with immunosuppression. Rheumatol. Int. 2011;31:327–337. doi: 10.1007/s00296-009-1292-x. - DOI - PubMed

LinkOut - more resources